Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2341 to 2355 of 9060 results

  1. Olomorasib in combination for untreated KRAS G12C mutation-positive unresectable advanced non-squamous non-small-cell lung cancer [GID-TA12001]

    Awaiting development Reference number: GID-TA12001 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Satralizumab for treating thyroid eye disease [ID6648]

    Awaiting development Reference number: GID-TA11860 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Olezarsen for treating severe hypertriglyceridaemia [GID-TA12016]

    Awaiting development Reference number: GID-TA12016 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Amlitelimab for treating moderate to severe atopic dermatitis in people 12 years and over [GID-TA12005]

    Awaiting development Reference number: GID-TA12005 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Grazax for treating allergic rhinitis and conjunctivitis caused by grass pollen in people 5 years and over [GID-TA12010]

    Awaiting development Reference number: GID-TA12010 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Emactuzumab for treating localised or diffuse tenosynovial giant cell tumours when surgery is unsuitable [GID-TA12000]

    Awaiting development Reference number: GID-TA12000 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Povorcitinib for treating non-segmental vitiligo [GID-TA12019]

    Awaiting development Reference number: GID-TA12019 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Povorcitinib for treating prurigo nodularis [GID-TA12018]

    Awaiting development Reference number: GID-TA12018 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Encaleret for treating autosomal dominant hypocalcaemia type 1 in people 16 years and over [GID-TA12008]

    Awaiting development Reference number: GID-TA12008 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Lonapegsomatropin for treating growth hormone deficiency in people 3 to 17 years [GID-TA12013]

    Awaiting development Reference number: GID-TA12013 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Lemborexan for treating insomnia [GID-TA12011]

    Awaiting development Reference number: GID-TA12011 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]

    Awaiting development Reference number: GID-TA11917 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

    Technology appraisal Reference number: TA582 Published:  24 May 2019

    Technology appraisal guidance
    In development

  14. Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]

    Awaiting development Reference number: GID-TA10662 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439]

    Awaiting development Reference number: GID-TA11325 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development